Switzerland is leading the way in the compassionate use of psychedelics like LSD and MDMA, with a dedicated group of psychiatrists administering these substances to patients. Despite the potential of ibogaine to help combat opioid dependence, research funding remains scarce in the U.S., even as its therapeutic benefits are recognized globally. The conversation highlights a growing awareness of the need for these ancient tools in modern medicine.
